Moderna Ships Coronavirus Vaccine for Clinical Trials

Moderna has shipped its first batch of mRNA-1273, a coronavirus vaccine, for a US Phase I clinical trial scheduled for April. The company prepared the candidate in 42 days from initial sequencing of the virus, which it called an "indoor record." It described mRNA-1273 as an mRNA vaccine that encodes for a prefusion stabilized form of the Spike (S) protein. Moderna, a Cambridge, MA company developing messenger RNA (mRNA) therapeutics and vaccines, said manufacturing of the initial batch was underwritten by Oslo's Coalition for Epidemic Preparedness Innovations (CEPI). More details.... Stock Symbol: (NSDQ: MRNA) Share this with colleagues: // //